152 related articles for article (PubMed ID: 27604660)
1. Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation.
Eikelis N; Hering D; Marusic P; Walton AS; Lambert EA; Sata Y; Krum H; Lambert GW; Esler MD; Schlaich MP
J Hum Hypertens; 2017 Apr; 31(4):248-252. PubMed ID: 27604660
[TBL] [Abstract][Full Text] [Related]
2. Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation.
Dörr O; Liebetrau C; Möllmann H; Gaede L; Troidl C; Rixe J; Hamm C; Nef H
Hypertension; 2014 May; 63(5):984-90. PubMed ID: 24470464
[TBL] [Abstract][Full Text] [Related]
3. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.
Yuan J; Guo Q; Qureshi AR; Anderstam B; Eriksson M; Heimbürger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2013 Sep; 28(9):2356-63. PubMed ID: 23828162
[TBL] [Abstract][Full Text] [Related]
4. Renal denervation in moderate treatment-resistant hypertension.
Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects two years after renal denervation in insulin resistant hypertensive patients. The Re-Shape CV-risk study.
Miroslawska AK; Gjessing PF; Solbu MD; Norvik JV; Fuskevåg OM; Hanssen TA; Steigen TK
Clin Nutr; 2021 Apr; 40(4):1503-1509. PubMed ID: 33743285
[TBL] [Abstract][Full Text] [Related]
6. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
[TBL] [Abstract][Full Text] [Related]
7. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension.
Lenski M; Mahfoud F; Razouk A; Ukena C; Lenski D; Barth C; Linz D; Laufs U; Kindermann I; Böhm M
Int J Cardiol; 2013 Nov; 169(6):418-24. PubMed ID: 24157238
[TBL] [Abstract][Full Text] [Related]
8. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet's disease.
Sertoglu E; Omma A; Yucel C; Colak S; Sandıkcı SC; Ozgurtas T
Scand J Clin Lab Invest; 2018 Oct; 78(6):443-449. PubMed ID: 30015524
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
Robak E; Sysa-Jedrzejewska A; Robak T
Mediators Inflamm; 2003 Oct; 12(5):293-8. PubMed ID: 14760936
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension.
Kylhammar D; Hesselstrand R; Nielsen S; Scheele C; Rådegran G
Scand J Rheumatol; 2018 Jul; 47(4):319-324. PubMed ID: 29528272
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for the prediction of blood pressure response to renal denervation: a long way to go.
Schlaich M
Hypertension; 2014 May; 63(5):907-8. PubMed ID: 24470460
[No Abstract] [Full Text] [Related]
12. Renal nerve ablation reduces augmentation index in patients with resistant hypertension.
Hering D; Lambert EA; Marusic P; Ika-Sari C; Walton AS; Krum H; Sobotka PA; Mahfoud F; Böhm M; Lambert GW; Esler MD; Schlaich MP
J Hypertens; 2013 Sep; 31(9):1893-900. PubMed ID: 23697964
[TBL] [Abstract][Full Text] [Related]
13. Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease.
Wieczór R; Gadomska G; Ruszkowska-Ciastek B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
J Zhejiang Univ Sci B; 2015 Nov; 16(11):948-56. PubMed ID: 26537213
[TBL] [Abstract][Full Text] [Related]
14. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
15. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
16. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer.
Chang YT; Chang MC; Wei SC; Tien YW; Hsu C; Liang PC; Tsao PN; Jan IS; Wong JM
Pancreas; 2008 Aug; 37(2):145-50. PubMed ID: 18665074
[TBL] [Abstract][Full Text] [Related]
17. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
Erturk I; Yesildal F; Acar R; Ozgurtas T; Saglam K
Saudi Med J; 2018 Jun; 39(6):586-591. PubMed ID: 29915853
[TBL] [Abstract][Full Text] [Related]
20. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.
Wieczór R; Wieczór AM; Gadomska G; Stankowska K; Fabisiak J; Suppan K; Pulkowski G; Budzyński J; Rość D
J Zhejiang Univ Sci B; 2016 Nov.; 17(11):842-849. PubMed ID: 27819131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
